Skip to main content

TNF inhibitor

      Hyrich:
      ETN originator vs biosimilar initiation
      - DAS28 - no signif change at B/L, 6mo, 12 mo.

      Switch?
      Matched pts in E
      1 month ago
      Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu
      The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. This study comparing the…
      Treating SpA
      A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension
      A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA
      If a mother has had TNFi during pregnancy, can a baby have a live oral rotavirus vaccine (usually at 2mo)?

      This claims
      1 month ago
      If a mother has had TNFi during pregnancy, can a baby have a live oral rotavirus vaccine (usually at 2mo)? This claims data suggests no increase in diarrhoea Adds to similarly reassuring 🇨🇦prospective cohort data https://t.co/2Tz9zRhPjz Vaccinate away! #ACR24 ABST0806 @RheumNow https://t.co/66OIAR8W6l
      Instead of just JAKi, why don't we look at all our RA meds and MACE risk

      FAERS data & reporting odds ratios here: a
      1 month ago
      Instead of just JAKi, why don't we look at all our RA meds and MACE risk FAERS data & reporting odds ratios here: all the caveats of voluntary reporting, so don't put too much weight, but... prednisone. Don't forget pred is really not great for MACE! #ACR24 ABST1981 @RheumNow https://t.co/L9SlPZF2Jd
      Should you worry about giving TNFi to RA pts after a cancer diagnosis?

      Medicare data with colorectal, lung, prostate Ca
      1 month ago
      Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow https://t.co/w58MNqRt1T
      Effective RA therapy is about more than just joints

      🇪🇸 RA cohort

      TNFi for first 24w led to:
      Lean mass index i.e.
      1 month ago
      Effective RA therapy is about more than just joints 🇪🇸 RA cohort TNFi for first 24w led to: Lean mass index i.e. muscle going up Fat mass index i.e. fat trending down Muscle & fat composition are important Systemic Rx can deliver systemic benefits #ACR24 ABST1348 @RheumNow https://t.co/mZjcHwxMgW
      Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution.
      Persistent higher doses earlier on
      1 month ago
      Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution. Persistent higher doses earlier on might dampen ICI response. @HSpecialSurgery ICI-IA (inflamm arthritis) cohort big diff in survival based on early steroid exposure #ACR24 ABST1989 @RheumNow https://t.co/3WAZ3ZLbFw
      Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies.

      All the epidemiological chal
      1 month ago
      Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies. All the epidemiological challenges here aside, it's a good reminder that with ORAL Surveillance it's *cardiovascular risk enriched pts* we're concerned about. #ACR24 ABST2264 @RheumNow https://t.co/vIXlrI3V2d
      ×